Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

FDA clears GtreeBNT to conduct phase III trial of RGN-137 in epidermolysis bullosa

Feb. 28, 2017

XBiotech's phase II study of MABp1 meets primary endpoint

Feb. 17, 2017

Signum Biosciences awarded NIAID grant to develop candidate for atopic dermatitis

Feb. 17, 2017

Galderma initiates phase II trial of NP-000888 for plaque and nail psoriasis

Feb. 17, 2017

FDA approves Siliq for plaque psoriasis

Feb. 16, 2017

MediWound reports favorable results from phase II study of NexoBrid

Feb. 10, 2017

Vyome Biosciences announces promising results for VB-1953

Feb. 8, 2017

Sirnaomics initiates first-in-human study of STP-705

Feb. 7, 2017

Merck KGaA discloses novel BTK inhibitors

Feb. 1, 2017

MediWound's phase II study of EscharEx meets primary endpoint

Feb. 1, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...